These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29018988)

  • 1. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.
    Corti A; Marcucci F; Bachetti T
    Pflugers Arch; 2018 Jan; 470(1):199-210. PubMed ID: 29018988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A: any relevance in neuroendocrine tumors?
    Kidd M; Bodei L; Modlin IM
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
    Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
    Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
    Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of Chromogranin A and Its Fragments in Biological Fluids.
    Curnis F; Colombo B; Corti A
    Methods Mol Biol; 2023; 2565():343-359. PubMed ID: 36205905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of tumor growth by circulating full-length chromogranin A.
    Curnis F; Dallatomasina A; Bianco M; Gasparri A; Sacchi A; Colombo B; Fiocchi M; Perani L; Venturini M; Tacchetti C; Sen S; Borges R; Dondossola E; Esposito A; Mahata SK; Corti A
    Oncotarget; 2016 Nov; 7(45):72716-72732. PubMed ID: 27683038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.
    Mahata SK; Corti A
    Ann N Y Acad Sci; 2019 Nov; 1455(1):34-58. PubMed ID: 31588572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
    Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
    Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
    HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
    Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
    J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
    Dittadi R; Gion M
    Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
    [No Abstract]   [Full Text] [Related]  

  • 16. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
    Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
    Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 18. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood].
    Glinicki P; Jeske W
    Endokrynol Pol; 2011; 62 Suppl 1():25-8. PubMed ID: 22125107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.